Welcome to our dedicated page for Numinus Wellness news (Ticker: NUMIF), a resource for investors and traders seeking the latest updates and insights on Numinus Wellness stock.
News and updates for Numinus Wellness Inc. (NUMIF) focus on its activities as a mental health care company centered on safe, evidence-based psychedelic-assisted therapies. Company announcements consistently describe efforts to advance behavioral health treatments through clinical trial research, practitioner training and technology-driven support for clinic-based delivery of psychedelic-assisted therapy.
Readers of the Numinus news feed can expect coverage of financial results, including quarterly updates that discuss revenue trends, gross margin, operating expenditures and cash position. These releases often highlight performance at Cedar Clinical Research, where Numinus manages clinical trials and provides research services for drug sponsors, as well as metrics related to its practitioner training business.
Corporate news also includes strategic and organizational developments. Numinus has reported the sale of its U.S. clinic network, the wind-down of non-operating subsidiaries through bankruptcy, and leadership changes such as the appointment of a new Chief Executive Officer and transitions in the Chief Financial Officer role. Additional updates describe accreditation milestones for its Psychedelic-Assisted Therapy Training Program in jurisdictions such as Oregon and Colorado, and engagements like Cedar Clinical Research’s participation in a Phase 3 multinational trial for CYB003 targeting Major Depressive Disorder.
Regulatory and capital markets developments are another recurring theme. Numinus has issued news about a cease trade order affecting its shares, its application to the British Columbia Securities Commission for revocation, and its stated intention to pursue relisting on another reputable exchange once conditions permit. For investors and observers, following NUMIF news provides insight into the company’s operational focus, restructuring steps, regulatory progress and evolving role in the psychedelic-assisted therapy ecosystem.
Numinus Wellness has completed its acquisition of Novamind, following necessary shareholder and court approvals. Numinus shareholders received 0.84 shares of Numinus for each Novamind share. The transaction enhances Numinus' operations, expanding its clinics and research facilities, and is projected to increase annual revenues to C$11.9 million. Key executive appointments include Reid Robison as Chief Clinical Officer and Paul Thielking as Chief Science Officer. The integration will allow for a broader range of mental health services and continued growth opportunities.
Novamind Inc. has successfully completed its acquisition by Numinus Wellness Inc., following the Supreme Court of British Columbia's final order. As part of this plan of arrangement, holders of Novamind shares will receive 0.84 of a Numinus share for each Novamind share they own. Consequently, Novamind shares will be delisted from the Canadian Securities Exchange, and the company plans to cease its public reporting obligations. This acquisition is anticipated to enhance Numinus's portfolio in the psychedelic medicine sector, positioning the combined entity for future growth.
Numinus Wellness Inc. (NUMIF) announced that its shareholders and Novamind shareholders have approved the acquisition of Novamind Inc. The transaction is set to be completed on or about June 10, 2022. Numinus aims to establish itself as a leader in mental wellness in North America, offering innovative therapies including Ketamine and psychedelic-assisted treatments. Over 98% of Numinus shareholders voted in favor of issuing up to 63,010,034 common shares to Novamind securityholders. The completion is pending approval from the British Columbia Supreme Court and standard closing conditions.
Numinus Wellness (TSX: NUMI) has received a positive recommendation from Institutional Shareholder Services (ISS) regarding its proposed acquisition of Novamind. ISS advises shareholders to vote "FOR" the share issuance related to this acquisition, emphasizing expected cost-saving synergies and strategic alignment in the same sector. The Numinus Special Shareholder Meeting is set for June 8, 2022, where shareholders will vote on the Share Issuance Resolution to authorize the issuance of up to 63,010,034 common shares in connection with the acquisition.
Numinus Wellness Inc. has received Health Canada approval to provide psilocybin-assisted therapy for treatment-resistant depression, marking a significant milestone as the first such treatment outside clinical trials. This therapy will be conducted at their Montreal clinic, using synthetic psilocybin sourced from Psygen Labs. The approval allows for innovative mental health treatment under Health Canada's Special Access Program (SAP), which facilitates access to psychedelic compounds for patients who have failed conventional treatments. Numinus aims to expand its offerings in Canada, enhancing access to evidence-based psychedelic therapies.
Numinus Wellness Inc. (TSX: NUMI) (OTC: NUMIF) will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 3:30 p.m. ET. Founder and CEO Payton Nyquvest will discuss Numinus’ innovative mental health treatments, including psychedelic-assisted therapies. Attendees can register for the event here. The chat will also be available via live webcast and archived on Numinus’ investor relations website.
Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) has mailed materials for its special meeting of shareholders scheduled for June 8, 2022. Shareholders are urged to vote by June 6. The meeting will address the proposed acquisition of Novamind Inc., which is expected to significantly enhance Numinus' revenue and profitability. Key benefits include a rapid expansion in the U.S. and an estimated C$3 million in annual cost savings. The interim court order for the transaction was granted on May 6, 2022.
Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF) announced its participation in key psychedelic industry conferences. Notably, at the Catalyst Summit 2022 in Kingston (May 20-22), several executives, including Michael Tan and Sharan Sidhu, will lead panel discussions. Additionally, Numinus will present at the Psychedelic Therapeutics and Drug Development Conference 2022 in Washington, DC (May 23-24), focusing on regulatory navigation. Lastly, at the From Research to Reality Summit in Toronto (May 27-29), research presentations will showcase findings on MDMA-assisted therapy and psychedelics' impact on opioid use.
Numinus Wellness (TSX: NUMI) (OTCQX: NUMIF) has announced the launch of Music As Medicine, a series of ceremonial concerts exploring the integration of music in psychedelic-assisted therapy. The initiative will feature artists like Jon Hopkins and East Forest and will take place in various cities in the U.S. and Canada, starting with an event in Los Angeles on May 21, 2022. This series aims to highlight music's role in mental health and connect communities through innovative therapeutic experiences.
Numinus Wellness reported a remarkable 240% year-over-year revenue growth to $0.8 million for Q2 2022, driven by acquisitions. Gross margin surged to 29.1% from 6.5% in Q1 2022. The company generated a gross profit of $228,759, marking a 349% increase from the prior quarter. Despite these gains, Numinus faced a loss of $7.8 million. The company concluded the quarter with $48.3 million in cash. A proposed acquisition of Novamind is anticipated to increase revenue significantly, positioning Numinus as a leader in psychedelic-assisted therapies.